Trial Profile
Phase II Study of Cetuximab and Lenalidomide in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Lenalidomide (Primary)
- Indications Head and neck cancer
- Focus Pharmacogenomic; Therapeutic Use
- 23 Jan 2014 As peer the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 22 Jun 2012 Planned End Date changed from 1 Feb 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 22 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.